About
Moebius Medical is a clinical-stage biotechnology company developing novel pain-relief treatments for osteoarthritis. The company's lead product, MM-II, is a patent-protected intra-articular biolubricant injection for the treatment of mild to moderate symptomatic knee osteoarthritis. MM-II consists of proprietary liposomes whose structure facilitates cartilage surface gliding, thus reducing pain and preventing further wear and friction that can lead to joint damage. MM-II has demonstrated its ability to reduce osteoarthritic pain in a double-blind, randomized controlled trial conducted at Hadassah Medical Center, Israel. In 2016, Sun Pharma and Moebius Medical entered into an exclusive worldwide licensing deal to further develop MM-II. Moebius Medical conducts the requisite preclinical studies and assumes responsibility for product development and manufacturing through the end of phase 2 studies. Sun Pharma assumes responsibility for clinical studies, regulatory submissions, and product commercialization. In December 2020, the FDA cleared the company's Investigational New Drug application to initiate a global multi-center phase IIb clinical trial of MM-II.
Funding history · 1 round · — total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Moebius Medical's primary focus?
- Moebius Medical is a clinical-stage biotechnology company developing novel pain-relief treatments for osteoarthritis. Its lead product is MM-II.
- What is Moebius Medical's lead product and its purpose?
- Moebius Medical's lead product, MM-II, is a patent-protected intra-articular biolubricant injection designed for the treatment of mild to moderate symptomatic knee osteoarthritis.
- When did Moebius Medical secure a licensing deal for MM-II, and with whom?
- In 2016, Moebius Medical entered into an exclusive worldwide licensing deal with Sun Pharma to further develop MM-II.
- What are the responsibilities of Moebius Medical and Sun Pharma under their licensing agreement?
- Moebius Medical is responsible for preclinical studies, product development, and manufacturing through the end of phase 2 studies. Sun Pharma handles clinical studies, regulatory submissions, and product commercialization.
- When did the FDA clear Moebius Medical's IND application for MM-II?
- In December 2020, the FDA cleared Moebius Medical's Investigational New Drug (IND) application to initiate a global multi-center phase IIb clinical trial of MM-II.
- When did Moebius Medical receive Fast Track designation for MM-II for osteoarthritis knee pain?
- On September 6, 2024, Sun Pharma and Moebius Medical announced that MM-II received Fast Track designation for the treatment of osteoarthritis knee pain.
- When were dual publications announced regarding MM-II's Phase 2b clinical trial results and mechanism of action?
- On April 24, 2025, Sun Pharma and Moebius Medical announced dual publications on MM-II's Phase 2b clinical trial results and its mechanism of action in osteoarthritis and cartilage.
- When was Moebius Medical founded and what was its first funding round?
- Moebius Medical was founded in August 2008 and secured a Seed round in the same month, with investors including Yissum Research Development, Pix Vine Capital, and RAD BioMed.